35
Targeted therapy
Assess patients
with stage IV
for appropriate
evidence-based
targeted therapy, all
patients with high
risk features, and
PS 0–2
Targeted therapies are
not cost effective in most
resource-constrained
regions unless patients are
being treated at enhanced
or maximal level
For guidance regarding the
use of PARPi refer to the
ASCO guideline
Cost-effectiveness
data are emerging,
awaiting outcomes
for primary therapy
maintenance
settings for PARPi
Basic Limited Enhanced
Patient
Category
Intervention
Category
Key
